drugset / Trial / NCT00035087

EPO906 Therapy in Patients With Advanced Colorectal Cancer

NCT00035087

Phase 2 Completed 62 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause colorectal cancer.

Timeline

Start
2002-05
Primary completion
2003-03
Completion
2003-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Patupilone Small molecule Intravenous

Indications